Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-FR Version v4-EN
Language French English
Date Updated 2021-03-16 2017-09-15
Drug Identification Number 02237815 02237815
Brand name ERWINASE ERWINASE
Common or Proper name Erwina L-asparaginase Erwina L-asparaginase
Company Name JAZZ PHARMACEUTICALS FRANCE SAS JAZZ PHARMACEUTICALS FRANCE SAS
Ingredients ASPARAGINASE ASPARAGINASE
Strength(s) 10000UNIT 10000UNIT
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS INTRAMUSCULAR INTRAVENOUS SUBCUTANEOUS
Packaging size 3 mL vials, 5 vials per carton 3 mL vials, 5 vials per carton
ATC code L01XX L01XX
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Other (Please describe in comments) Demand increase for the drug.
Anticipated start date 2017-09-14 2017-09-14
Actual start date
Estimated end date Unknown Unknown
Actual end date 2021-03-10
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Reason for ongoing shortage in Canada (less than 3-months supply) due to global capacity constraints in manufacturing leading to just-in time supply with intermittent shortages. Additionally demand has increased.
Health Canada comments